437 related articles for article (PubMed ID: 20523363)
1. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Germano IM; Emdad L; Qadeer ZA; Binello E; Uzzaman M
Cancer Gene Ther; 2010 Sep; 17(9):664-74. PubMed ID: 20523363
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
3. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Ziegler DS; Keating J; Kesari S; Fast EM; Zawel L; Ramakrishna N; Barnes J; Kieran MW; Veldhuijzen van Zanten SE; Kung AL
Neuro Oncol; 2011 Aug; 13(8):820-9. PubMed ID: 21724651
[TBL] [Abstract][Full Text] [Related]
4. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.
Soritau O; Tomuleasa C; Aldea M; Petrushev B; Susman S; Gheban D; Ioani H; Cosis A; Brie I; Irimie A; Kacso G; Florian IS
J BUON; 2011; 16(2):282-9. PubMed ID: 21766499
[TBL] [Abstract][Full Text] [Related]
5. In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas.
Uzzaman M; Keller G; Germano IM
Neuro Oncol; 2009 Apr; 11(2):102-8. PubMed ID: 18676359
[TBL] [Abstract][Full Text] [Related]
6. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
7. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
8. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
10. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.
Germano IM; Binello E
J Neurooncol; 2009 May; 93(1):79-87. PubMed ID: 19430884
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Koukourakis GV; Kouloulias V; Zacharias G; Papadimitriou C; Pantelakos P; Maravelis G; Fotineas A; Beli I; Chaldeopoulos D; Kouvaris J
Molecules; 2009 Apr; 14(4):1561-77. PubMed ID: 19384285
[TBL] [Abstract][Full Text] [Related]
14. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Jiang G; Sun C; Li RH; Wei ZP; Zheng JN; Liu YQ
J Cancer Res Clin Oncol; 2015 Jan; 141(1):75-85. PubMed ID: 25103017
[TBL] [Abstract][Full Text] [Related]
16. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Hingtgen S; Ren X; Terwilliger E; Classon M; Weissleder R; Shah K
Mol Cancer Ther; 2008 Nov; 7(11):3575-85. PubMed ID: 19001440
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
[TBL] [Abstract][Full Text] [Related]
18. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Chaponis D; Barnes JW; Dellagatta JL; Kesari S; Fast E; Sauvageot C; Panagrahy D; Greene ER; Ramakrishna N; Wen PY; Kung AL; Stiles C; Kieran MW
J Neurooncol; 2011 Aug; 104(1):179-89. PubMed ID: 21246394
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Hassouna I; Sperling S; Kim E; Schulz-Schaeffer W; Rave-Fränk M; Hasselblatt M; Jelkmann W; Giese A; Ehrenreich H
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):927-34. PubMed ID: 19014782
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
